LeMaitre Vascular Raises FY2026 GAAP EPS Guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 Est; Narrows FY2026 Sales Guidance from $276.000M-$284.000M to $277.000M-$283.000M vs $279.492M Est

LeMaitre Vascular (NASDAQ:LMAT) raises FY2026 GAAP EPS guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 analyst estimate. Narrows FY2026 sales outlook from $276.000 million-$284.000 million to $277.000 million-$283.000 million vs $279.492 million estimate.